PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
8610637-2	1996	A phase II trial of a continuous infusion of cisplatin, 5-FU, and high dose folinic acid (PFL) as induction chemotherapy in patients with previously untreated, locally advanced HN cancer was performed in an attempt to confirm the encouraging results reported by Dana Farber investigators using an identical regimen.	Leucovorin	76-88	profilin 2	Homo sapiens	90-93	
12598339-1	2003	BACKGROUND: To study prospectively the activity of primary chemotherapy with cisplatin, fluorouracil and leucovorin (PFL) in patients with paranasal cancer receiving surgery and postoperative radiotherapy.	Leucovorin	105-115	profilin 2	Homo sapiens	117-120	
12598339-3	2003	PFL (leucovorin 250 mg/m2/day for 5 days as a 120 h continuous infusion (c.i.	Leucovorin	5-15	profilin 2	Homo sapiens	0-3	
9166490-1	1995	PURPOSE: The combination of cisplatin, 5-fluorouracil, and leucovorin (PFL) has been reported to have a 29% response rate in advanced non-small cell lung cancer.	Leucovorin	59-69	profilin 2	Homo sapiens	71-74	
8635020-1	1995	BACKGROUND: Cisplatin, 5-flourouracil (5-FU), and leucovorin (PFL) chemotherapy has been reported to be effective in the treatment of cancers but severe mucositis or neutropenia are dose limiting toxicities.	Leucovorin	50-60	profilin 2	Homo sapiens	62-65	
8748007-0	1996	Pilot study of ambulatory infusional delivery of a multidrug regimen: cisplatin, 5-fluorouracil and leucovorin (PFL) +/- etoposide.	Leucovorin	100-110	profilin 2	Homo sapiens	112-115	
8293384-3	1994	Based on high response rates of Cisplatin, 5-Fluororacil and Leucovorin (PFL) in patients with advanced squamous cell cancers of the head and neck, we tested a new outpatient PFL chemotherapy program in patients with advanced NPC.	Leucovorin	61-71	profilin 2	Homo sapiens	73-76	
8313319-1	1994	BACKGROUND: Cisplatin, 5-fluorouracil, and leucovorin (PFL) have demonstrated synergistic activity in preclinical models.	Leucovorin	43-53	profilin 2	Homo sapiens	55-58	
7973772-1	1994	In a randomized phase II study by the Cancer and Leukemia Group B, the cisplatin/5-fluorouracil/leucovorin (PFL) combination produced a 29% response rate in advanced, unresectable non-small cell lung cancer.	Leucovorin	96-106	profilin 2	Homo sapiens	108-111	
1688926-2	1990	Therefore, the addition of LV to cisplatin and 5-FU (PFL) may increase the activity of that combination in head and neck cancer.	Leucovorin	27-29	profilin 2	Homo sapiens	53-56	
8274261-2	1994	OBJECTIVE: To evaluate the activity and toxicity of the drug combination cisplatin, fluorouracil by continuous infusion, and high-dose oral leucovorin calcium (PFL) as induction chemotherapy in patients with advanced and untreated squamous cell head and neck (SCHN) cancer.	Leucovorin	140-158	profilin 2	Homo sapiens	160-163	
2297193-1	1990	STUDY OBJECTIVE: To study the activity of continuous infusion cisplatin, 5-fluorouracil, and high-dose leucovorin (PFL) as induction chemotherapy in patients with previously untreated, advanced squamous cell carcinoma of the head and neck.	Leucovorin	103-113	profilin 2	Homo sapiens	115-118	
8426214-1	1993	PURPOSE: To increase the activity of cisplatin, fluorouracil (5-FU), and leucovorin (PFL) through further biochemical modulation and study the pharmacologic interaction of 5-FU and interferon alfa-2b (IFN).	Leucovorin	73-83	profilin 2	Homo sapiens	85-88	
21612748-7	2011	Here we re port a case of a 64-year-old Taiwanese male patient with neuroendocrine carcinoma of the gall bladder who received combined chemoradiotherapy (CCRT) with cisplatin, 5- fluorouracil and leucovorin (PFL) from June 2009 un til now, and whose disease is stable.	Leucovorin	196-206	profilin 2	Homo sapiens	208-211